Effect of Open-Label Everolimus in Patients with Advanced Neuroendocrine Tumors After Disease Progression on Somatostatin Analog: A RADIANT-2 Analysis

Edward M. Wolin1; John D. Hainsworth2; Dieter Hörsch3; Gabriele Luppi4; Valentine Jehl5; Marc Peeters6

1Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA
2Sarah Cannon Research Institute, Nashville, Tennessee, 37203, USA
3Klinik für Innere Medizin, Gastroenterologie und Endokrinologie, Zentrum für Neuroendokrine Tumore, Zentralklinik Bad Berka GmbH, Bad Berka, 99437, Germany
4Azienda Ospedaliero-Universitaria, Modena, 41124, Italy
5Novartis Pharma AG, Basel, CH-4002, Switzerland
6Department of Oncology, Antwerp University Hospital, Edegem, 2650, Belgium

Background: In the RADIANT-2 study (NCT00412061), everolimus + octreotide LAR (E+O) resulted in a clinically meaningful increase in median progression-free survival (PFS; by adjudicated central review) of 5.1 months versus placebo + octreotide LAR (P+O) in patients with advanced NET with a history of carcinoid syndrome. Investigator-assessed PFS was 12.0 months for E+O compared with 8.6 months for P+O, respectively. Upon radiological disease progression (as per investigator assessment), P+O patients could cross over to open-label E+O. Here we present the outcomes of P+O patients who crossed over to open-label E+O.

Methods: 429 patients were randomly assigned: 216 to E (10 mg/d) + O (30 mg IM q 28 d) and 213 to P+O.

Results: Upon radiological disease progression per investigator assessment, 124 P+O patients crossed over to open-label E+O. Median duration of treatment with open-label E+O was 26.3 weeks (range, 1-133); 34 patients (27.4%) received open-label E+O for ≥12 months. Median time from randomization to crossover to open-label E+O was 14.1 months. Median PFS in the open-label E+O group, calculated from time of crossover and assessed by local investigators, was 10.1 months (95% CI, 8.0-13.5). Adverse events were similar to those reported for the E+O arm during the double-blind phase of the study.

Conclusions: Patients with NET enrolled in the RADIANT-2 study who received open-label E+O after progressing on P+O had median PFS of 10.1 months with no unexpected adverse events.

Supported by Novartis